Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

895

Citations

18

References

2017

Year

Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,

MedicineRandomised Phase 3PathologyAlectinib Versus CrizotinibBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyCancer Growth

References

	Year	Citations

Page 1

Page 1